Clinical trials: Stroke Assessment
Ischemic Stroke
Effectiveness and Safety Trial of a New Ischemic Stroke Treatment Within 24 Hours From Stroke Onset (NEST-2)
The purpose of this pivotal study is to demonstrate safety and effectiveness of the NeuroThera® Laser System (referred to hereafter as NTS) in the treatment of Subjects diagnosed with acute ischemic stroke.
- Trial name
- NCT00419705
- Testing
- NeuroThera® Laser System
- Where
- 58 sites in United States, Germany and 2 more
- Volunteers
- 660 people
- Sponsor
- PhotoThera, Inc
Acute Ischemic Stroke
Efficacy and Safety Trial of Transcranial Laser Therapy Within 24 Hours From Stroke Onset (NEST-3)
The purpose of this pivotal study is to demonstrate safety and efficacy of transcranial laser therapy (TLT) with the NeuroThera® Laser System in the treatment of subjects diagnosed with acute ischemic stroke.
- Trial name
- NEST-3 (NCT01120301)
- Testing
- NeuroThera® Laser System
- Where
- 60 sites in United States, Austria and 8 more
- Volunteers
- 1,000 people
- Sponsor
- PhotoThera, Inc
Heat Stroke
Efficacy and Safety of Ryanodex® (EGL-4104) as Adjuvant Treatment in Subjects With Exertional Heat Stroke (EHS)
Study EGL-4104-C-1502 is a phase 2, single-site, open-label, randomized, 2-arm parallel study of Ryanodex for the adjuvant treatment of exertional heat stroke (EHS) administered intravenously (IV), to current standard of care…
- Trial name
- NCT02513095
- Testing
- Dantrolene sodium for injectable suspension
- Where
- Saudi Arabia
- Volunteers
- 34 people
- Sponsor
- Eagle Pharmaceuticals, Inc.
Chronic Stroke
An Open-labeled Phase II Study to Evaluate the Efficacy and Safety of GXNPC-1 in Patients with Chronic Stroke
The primary objective of this study is to evaluate the efficacy for subjects with chronic stroke after GXNPC-1 injection.
- Trial name
- NCT04088149
- Testing
- GXNPC1
- Where
- Taiwan
- Volunteers
- 12 people
- Sponsor
- Gwo Xi Stem Cell Applied Technology Co., Ltd.
Hemorrhagic Stroke
Esmolol for the Treatment of Hypertension After Intracerebral Hemorrhage Study (ETHICHS)
Because of its pharmacokinetic characteristics, such as short half-life and its safety profile, esmolol hydrochloride is a beta blocker suitable for venous use in the form of continuous infusion.
- Trial name
- ETHICHS (NCT03743103)
- Testing
- Brevibloc, 10 Mg/mL Intravenous Solution, Nitroprusside, Sodium
- Where
- 7 sites in Brazil
- Volunteers
- 20 people
- Sponsor
- Cristália Produtos Químicos Farmacêuticos Ltda.
Cerebral Ischemia, Cerebral Infarction
Efficacy of Sovateltide (PMZ-1620) in Patients of Acute Ischemic Stroke
In the present prospective, multicentric, randomized, double-blind, parallel, saline-controlled phase II clinical study; the investigators plan to evaluate the efficacy of sovateltide (IRL-1620 or PMZ-1620) therapy along with…
- Conditions
- Cerebral Ischemia, Cerebral Infarction, Stroke, Acute
- Trial name
- NCT04047563
- Testing
- Normal Saline along with standard treatment, PMZ-1620 (sovateltide) along with standard treatment
- Where
- 11 sites in India
- Volunteers
- 158 people
- Sponsor
- Pharmazz, Inc.
Acute Ischemic Stroke Patients
Evaluation of rSO2 Between Frontal Lesion Area and Normal Area of Brain by NIRSITX Using NIRS in Acute Ischemic Stroke Patients.
The clinical trial is for acute ischemic stroke patients measuring cerebral oxygen saturation (rSO2) values using pulse oximeter of near-infrared spectroscopy in the frontal lesion area and normal area of brain.
- Trial name
- fNIRS (NCT06250608)
- Testing
- Pulse oximeter, NIRSITX
- Where
- 2 sites in South Korea
- Volunteers
- 35 people
- Sponsor
- OBELAB, Inc.
Upper Limb Spasticity
Efficacy and Safety of DaxibotulinumtoxinA for Injection for the Treatment of Adult Upper Limb Spasticity
This is a randomized, Double-Blind, Placebo-Controlled, Parallel Group, Dose-Ranging, trial to Evaluate the Efficacy and Safety of DaxibotulinumtoxinA for Injection for the Treatment of Upper Limb Spasticity in Adults After…
- Trial name
- JUNIPER (NCT03821402)
- Testing
- DAXI for injection 250 U, DAXI for injection 375 U, DAXI for injection 500 U
- Where
- 26 sites in United States
- Volunteers
- 83 people
- Sponsor
- Revance Therapeutics, Inc.
Acute Ischemic Stroke
Optimizing Reperfusion to Improve Outcomes and Neurologic Function
The goal of this study is to evaluate the safety and efficacy of JX10 versus placebo in participants with Acute Ischemic Stroke (AIS) who present for care within 4.5 to 24 hours. The main question the study aims to answer are: 1.
- Trial name
- ORION (NCT06990867)
- Testing
- JX10
- Where
- 104 sites in United States, Belgium and 19 more
- Volunteers
- 740 people
- Sponsor
- Corxel Pharmaceuticals
Stroke
Evaluation of an Individualised Written Education Package for Stroke Patients
The primary aim of the randomised controlled trial was to evaluate the effectiveness of a tailored written education package ("What you need to know about stroke") on the outcomes of: Knowledge about stroke, self-efficacy…
- Trial name
- NCT00126295
- Testing
- 'What you need to know about stroke' education package
- Where
- Australia
- Volunteers
- 130 people
- Sponsor
- Medical Benefits Fund of Australia
Atrial Fibrillation (AF)
Stroke and Systemic Embolism Prevention in Adult Participants With Atrial Fibrillation for Whom Oral Anticoagulation is Unsuitable
This study is researching 2 different experimental drugs called REGN7508 and REGN9933 (called "study drugs"). The study is focused on people who have atrial fibrillation, which means that the heart beats too fast and unevenly.
- Trial name
- ROXI-INCLINE (NCT07430956)
- Testing
- REGN7508, REGN9933
- Where
- 44 sites in United States, Canada
- Volunteers
- 2,628 people
- Sponsor
- Regeneron Pharmaceuticals
Atrial Fibrillation
Study to Evaluate the Use of Direct Oral Anticoagulants in UK Clinical Practice For Patients With a First Stroke Attributable to Nonvalvular Atrial Fibrillation
National Institute of Health and Care Excellence (NICE) guidance recommends anticoagulation for stroke prevention in high risk patients with nonvalvular atrial fibrillation (AF).
- Trial name
- NCT05262322
- Testing
- Edoxaban, Apixaban, Rivaroxaban
- Where
- 8 sites in United Kingdom
- Volunteers
- 234 people
- Sponsor
- Daiichi Sankyo UK Ltd, a Daiichi Sankyo Company
Heart Attack and Stroke
Emergency Call for Heart Attack and Stroke (ECHAS) - ECHAS One Study
ECHAS One will test the use of a smartphone app to assist patients to decide if it is necessary to call for emergency care with symptoms that could represent a heart attack or stroke.
- Trial name
- ECHAS (NCT05230069)
- Testing
- Interview
- Volunteers
- 200 people
- Sponsor
- Emergency Call for Heart Attack and Stroke (ECHAS)
Acute Ischemic Stroke
PREVAIL: PREvention of VTE After Acute Ischemic Stroke With LMWH Enoxaparin ( - VTE: Venous Thromboembolism - LMWH: Low Molecular Weight Heparin)
Primary objective: To demonstrate superiority of enoxaparin 40 mg sc qd in the prevention of VTE compared to UFH (unfractionated heparin) 5000 U sc q12 hours given for 10 ± 4 days following acute ischemic stroke.
- Trial name
- NCT00077805
- Testing
- Enoxaparin sodium
- Where
- 15 sites in United States, Australia and 13 more
- Sponsor
- Sanofi
Exertional Heat Stroke
Study to Assess the Efficacy and Safety of Ryanodex as Adjuvant Treatment in Subjects With EHS
A double-blind, parallel study of Ryanodex for the adjuvant treatment of exertional heat stroke (EHS) compared to current Standard of Care (SOC) for EHS.
- Trial name
- NCT03600376
- Testing
- Ryanodex and Standard of Care, Standard of Care
- Where
- 4 sites in Saudi Arabia
- Volunteers
- 17 people
- Sponsor
- Eagle Pharmaceuticals, Inc.
Stroke
Efficacy and Safety Study of Desmoteplase to Treat Acute Ischemic Stroke
The purpose of the study is to determine whether desmoteplase is effective and safe in the treatment of patients with acute ischaemic stroke when given within 3-9 hours from onset of stroke symptoms.
- Trial name
- DIAS-3 (NCT00790920)
- Testing
- Desmoteplase
- Where
- 102 sites in Australia, Austria and 15 more
- Volunteers
- 492 people
- Sponsor
- H. Lundbeck A/S
Acute Ischemic Stroke
Safety and Efficacy Evaluation of the iNstroke 4F Thromboaspiration Catheter in Patients With Acute Ischaemic Stroke Due to Primary Distal Medium Vessel Occlusions (DMVO)
Prospective, Single-arm, Multi-centre Study to Evaluate the Efficacy and Safety of the iNstroke 4F Thromboaspiration Catheter in Patients with Acute Ischaemic Stroke due to Primary Distal Medium Vessel Occlusions.
- Trial name
- 4-NiVO (NCT07357285)
- Testing
- Thromboaspiration catheter
- Where
- 11 sites in Germany, Hungary and 1 more
- Volunteers
- 57 people
- Sponsor
- iVascular S.L.U.
Ischemic Stroke, Acute Stroke
The Imperative Trial: Treatment of Acute Ischemic Stroke With the Zoom Reperfusion System
The trial is designed to assess the safety and efficacy of using the Zoom Reperfusion System in subjects diagnosed with acute ischemic stroke and undergoing a thrombectomy procedure within 8 hours of last known well.
- Trial name
- NCT04129125
- Testing
- Zoom Reperfusion System
- Where
- 28 sites in United States
- Volunteers
- 328 people
- Sponsor
- Imperative Care, Inc.
Cerebral Apoplexy
Single-dose Incremental Intravenous Injection of SY-007 in Healthy Subjects
This study is a single-dose incremental, randomized, double-blind, parallel, placebo-controlled study on safety, tolerance and pharmacokinetics healthy subjects.
- Trial name
- NCT04111523
- Testing
- SY-007
- Where
- China
- Volunteers
- 78 people, healthy volunteers welcome
- Sponsor
- Suzhou Yabao Pharmaceutical R&D Co., Ltd.
Acute Ischemic Stroke
Safety and Efficacy of SHPL-49 Injection in Participants With Acute Ischemic Stroke
This study is designed to determine the safety and efficacy of SHPL-49 intravenous infusion for 7 consecutive days in the treatment of acute ischemic stroke subjects.
- Trial name
- NCT06202378
- Testing
- 3 ampoules of SHPL-49 Injection, 6 ampoules of SHPL-49 Injection, 0.9% Sodium Chloride Injection
- Where
- 16 sites in China
- Volunteers
- 270 people
- Sponsor
- Shanghai Hutchison Pharmaceuticals Limited